Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting

Arthritis Care and Research

Volumn 68, Issue 5, 2016, Pages 629-637

  An, Jaejin ^a   Cheetham, T Craig ^b   Reynolds, Kristi ^b   Alemao, Evo ^c   Kawabata, Hugh ^c   Liao, Katherine P ^d   Solomon, Daniel H ^d  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b KAISER PERMANENTE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK MANAGEMENT; UNITED STATES; AGED; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMORBIDITY; COMPLICATION; HEALTH INSURANCE; MIDDLE AGED; PATIENT ATTITUDE; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; COMORBIDITY; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OSTEOARTHRITIS; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS; UNITED STATES;

EID: 84964526635     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22740     Document Type: Article

References (29)

1. Wolfe F, Michaud K., The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008; 58: 2612-21.
2. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F., Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59: 1090-6.
3. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al., The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52: 412-20.
4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
5. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D., Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71: 1524-9.
6. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
7. Gkaliagkousi E, Gavriilaki E, Doumas M, Petidis K, Aslanidis S, Stella D., Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. J Clin Rheumatol 2012; 18: 422-30.
8. Desai SS, Myles JD, Kaplan MJ., Suboptimal cardiovascular risk factor identification and management in patients with rheumatoid arthritis: a cohort analysis. Arthritis Res Ther 2012; 14: R270.
9. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73: 62-8.
10. Faden G, Viapiana O, Fischetti F, Faganello G, Gatti D, Tarantini L, et al., Cardiovascular risk stratification and management of patients with rheumatoid arthritis in clinical practice: the "EPIDAURO registry." Int J Cardiol 2014; 172: 534-6.
11. Toms TE, Panoulas VF, Douglas KM, Griffiths H, Sattar N, Smith JP, et al., Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 2010; 69: 683-8.
12. Bartels CM, Kind AJ, Thorpe CT, Everett CM, Cook RJ, McBride PE, et al., Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities: a Medicare analysis. Semin Arthritis Rheum 2012; 42: 9-16.
13. Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, et al., Rheumatoid arthritis and cardiovascular disease. Am Heart J 2013; 166: 622-8.
14. Charles-Schoeman C., Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheum Rep 2012; 14: 455-62.
15. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, et al., Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012; 41: 535-44.
16. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al., Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011; 13: R32.
17. Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, et al., Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.
18. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB., Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
19. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
20. American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014; 37 Suppl 1: S14-80.
21. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al., Quality of care for patients with rheumatoid arthritis. JAMA 2000; 284: 984-92.
22. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al., US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Medical Care 2010; 48: 923-33.
23. Monk HL, Muller S, Mallen CD, Hider SL., Cardiovascular screening in rheumatoid arthritis: a cross-sectional primary care database study. BMC Family Practice 2013; 14: 150.
24. Chi MD, Vansomphone SS, Liu IL, Cheetham C, Green KR, Scott RD, et al., Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care 2014; 20: e105-12.
25. Ritchey MD, Wall HK, Gillespie C, George MG, Jamal A, and the Division for Heart Disease and Stroke Prevention. Million hearts: prevalence of leading cardiovascular disease risk factors. United States, 2005-2012. MMWR 2014; 63: 462-7.
26. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2014; 129 Suppl 2: S1-45.
27. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.
28. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE., Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1310-4.
29. Choy E, Sattar N., Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.